The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwHRMM 2026 | Could long-read sequencing change the way we assign risk in myeloma?
Sarah Gooding, MD, PhD, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK, discusses how long-read sequencing could change the way risk is assigned in multiple myeloma, highlighting the current inequality in accessing risk designation tests globally. Dr Gooding explains that the idea is to be able to deliver all necessary risk designation information to determine high-risk myeloma and predict response to individual therapies. This interview took place at the 3rd International Workshop on High-Risk Multiple Myeloma (iwHRMM 2026), held in Charleston, SC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
